Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Apr 16, 2008

Bio-Bridge and JRS to Form a Joint Venture for Biomaterial Supply in China

  • Bio-Bridge Science and JR Scientific report plans to invest RMB 10 million, or $1.43 million, to set up a joint venture that will supply biomaterials in China and other countries.

    The firms signed a a nonbinding memorandum of understanding to effect the formation of the JV, which will be carried out with other investors in China. JRS has agreed to transfer technology and know-how to the JV. The new entity will produce culture medium, serum, and other biomaterials for sale.

    The JV will serve as a source of revenue for Bio-Bridge. With an HIV-PV vaccine for prevention and treatment of HIV in preclinical testing, Bio-Bridge will also gain a new supplier for the relevant vaccine material.

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »